

what is claimed is:

1. A method of assessing the effectiveness of non-nucleoside reverse transcriptase antiretroviral therapy of an HIV-infected patient comprising:

(a) collecting a plasma sample from the HIV-infected patient; and

(b) evaluating whether the plasma sample contains nucleic acid encoding HIV reverse transcriptase having a mutation at codon 236;

in which the presence of the mutation correlates with decreased susceptibility to delavirdine and little or no change in nevirapine susceptibility.

2. The method of claim 1, wherein the mutation at codon 236 codes for a leucine.

3. The method of claim 1, wherein reverse transcriptase has an additional mutation(s) at codon 103, codon 181 or a combination thereof.

4. The method of claim 3, wherein the mutation at codon 103 encodes an asparagine (N) and the mutation at codon 181 encodes a cysteine (C).

BEST AVAILABLE COPY

5. The method of claim 1, wherein the HIV-infected patient is being treated with an antiretroviral agent.

6. A method of assessing the effectiveness of antiretroviral therapy of an HIV-infected patient comprising:

(a) collecting a biological sample from an HIV-infected patient; and

(b) evaluating whether the biological sample comprises nucleic acid encoding HIV reverse transcriptase having a mutation at codon 225;

in which the presence of the mutation correlates with an increase in delavirdine susceptibility and little or no change in nevirapine susceptibility.

7. The method of claim 6 wherein the mutated codon 225 encodes a histidine (H).

8. The method of claim 6, wherein the HIV-infected patient is being treated with an antiretroviral agent.

9. The method of claim 6, wherein the reverse transcriptase has an additional mutation(s) at codon 103, 181 or a combination thereof.

Sub. C. 11

Sub. C17

- in which the presence of the mutation correlates with an increase in delavirdine susceptibility and a decrease in nevirapine susceptibility.

11. The method of claim 10, wherein the mutation at codon 190 encodes an alanine or a serine.

12. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

- (a) introducing a resistance test vector comprising a patient-derived segment further comprising a mutation at codon 236 and a mutation at codon 103 and/or 181 and an indicator gene into a host cell;
- (b) culturing the host cell from step (a);
- (c) measuring the indicator in a target host cell; and
- (d) comparing the measurement of the indicator from step (c) with the measurement of the indicator measured when steps (a) - (c) are carried out in the

absence of the candidate antiretroviral drug compound;

wherein a test concentration of the candidate antiretroviral drug compound is present at steps (a) - (c); at steps (b) - (c); or at step (c).

13. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

(a) introducing a resistance test vector comprising a patient-derived segment further comprising a mutation at codon 225 and a mutation at codon 103 and an indicator into a host cell;

(b) culturing the host cell from step (a);

(c) measuring the indicator in a target host cell; and

(d) comparing the measurement of the indicator from step (c) with the measurement of the indicator measured when steps (a) - (c) are carried out in the absence of the candidate antiretroviral drug compound;

wherein a test concentration of the candidate antiretroviral drug compound is present at steps (a) - (c); at steps (b) - (c); or at step (c).

14. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

(a) introducing a resistance test vector comprising a patient-derived segment which encodes the reverse transcriptase having a mutation at codon 236 and an indicator gene into a host cell;

(b) culturing the host cell from step (a);

(c) measuring expression of the indicator gene in a target host cell; and

(d) comparing the expression of the indicator gene from step (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the candidate anti-viral drug compound,

wherein a test concentration of the candidate anti-viral drug compound is present at steps (a)-(c); at steps (b)-(c); or at step (c).

15. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

(a) introducing a resistance test vector comprising a patient-derived segment which encodes the reverse transcriptase having a mutation at codon 225, and an indicator gene into a host cell;

(b) culturing the host cell from step (a);

(c) measuring expression of the indicator gene in a target host cell; and

Sub. C17

(d) comparing the expression of the indicator gene from step (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the candidate anti-viral drug compound,

wherein a test concentration of the candidate anti-viral drug compound is present at steps (a)-(c); at steps (b)-(c); or at step (c).

16. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

(a) introducing a resistance test vector comprising a patient-derived segment further comprising reverse transcriptase having a mutation at codon 190, and an indicator gene into a host cell;

(b) culturing the host cell from step (a);

(c) measuring expression of the indicator gene in a target host cell; and

(d) comparing the expression of the indicator gene from step (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the candidate anti-viral drug compound;

wherein a test concentration of the candidate anti-viral drug compound is present at steps (a)-(c); at steps (b)-(c); or at step (c).

Sub c'17

17. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutation at codon 190 and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

18. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutation at codon 225 and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

19. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutation at codon 236 and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

20. The resistance test vector of claim 17, wherein the patient-derived segment having a mutation at codon 190 further comprises a mutation at codon 103.

21. The resistance test vector of claim 18, wherein the patient-derived segment having a mutation at codon 225 further comprises a mutation at codon 103.

22. The resistance test vector of claim 17, wherein the patient-derived segment having a mutation at codon 236 further comprises a mutation at codon 103 and/or 181.

Sub C17

669250-6620260

Sub. C17

(b) evaluating whether the plasma sample contains nucleic acid encoding HIV reverse transcriptase having a mutation at codon 230;

2



2



27. The method of claim 23, wherein the HIV-infected patient is being treated with an antiretroviral agent.

28. A method of assessing the effectiveness of non-nucleoside reverse transcriptase antiretroviral therapy of an HIV-infected patient comprising:

(a) collecting a plasma sample from the HIV-infected patient; and

(b) evaluating whether the plasma sample contains nucleic acid encoding HIV reverse transcriptase having a mutation at codon 181;

in which the presence of the mutation correlates with decreased susceptibility to delavirdine and nevirapine and little or no change in efavirenz susceptibility.

29. The method of claim 28, wherein the mutation at codon 181 codes for a cysteine (C).

30. The method of claim 28, wherein reverse transcriptase has an additional mutation(s) at codon 98, codon 106, codon 227 or a combination thereof.

31. The method of claim 30, wherein the mutation at codon 98 encodes a glycine (G), the mutation at codon 106 encodes an alanine (A) and the mutation at codon 227 encodes a leucine (L).

32. The method of claim 28, wherein the HIV-infected patient is being treated with an antiretroviral agent.

33. A method of assessing the effectiveness of non-nucleoside reverse transcriptase antiretroviral therapy of an HIV-infected patient comprising:

(a) collecting a plasma sample from the HIV-infected patient; and

(b) evaluating whether the plasma sample contains nucleic acid encoding HIV reverse transcriptase having a mutation at codon 188,

in which the presence of the mutation correlates with decreased susceptibility to delavirdine and nevirapine and efavirenz.

34. The method of claim 33, wherein the mutation at codon 188 codes for a leucine (L), cysteine (C) or histidine (H).

35. The method of claim 33, wherein reverse transcriptase has an additional mutation(s) at codon 138, codon 103, codon 100 or a combination thereof.

36. The method of claim 35, wherein the mutation at codon 138 encodes an alanine (A), the mutation at codon 103 encodes an asparagine (N) and the mutation at codon 100 encodes an isoleucine (I).

37. The method of claim 33, wherein the HIV-infected patient is being treated with an antiretroviral agent.

669250-66202660

Sub C1

[illegible]

- (b) evaluating whether the plasma sample contains nucleic acid encoding HIV reverse transcriptase having a mutation at codon 190;

in which the presence of the mutation correlates with increased susceptibility to delavirdine and decreased susceptibility to nevirapine and efavirenz.

39. The method of claim 38, wherein the mutation at codon 190 codes for an alanine (A) or a serine (S).

40. The method of claim 38, wherein reverse transcriptase has an additional mutation(s) at codon 98, codon 101 or codon 103 or a combination thereof.

41. The method of claim 40, wherein the mutation at codon 98 encodes a glycine (G), 101 encodes a glutamic acid (E) and 103 encodes an asparagine (N).

42. The method of claim 38, wherein the HIV-infected patient is being treated with an antiretroviral agent.

[illegible]

(b) evaluating whether the plasma sample contains nucleic acid encoding HIV reverse transcriptase having a mutation at codon 106;

44. The method of claim 43, wherein the mutation at codon 106 encodes an alanine (A).

45. The method of claim 43, wherein reverse transcriptase has an additional mutation(s) at codon 227 and codon 189 or a combination thereof.

46. The method of claim 45, wherein the mutation at codon 227 encodes a leucine (L) and 189 encodes a leucine (L).

47. The method of claim 43, wherein the HIV-infected patient is being treated with an antiretroviral agent.

	1980	1981	1982	1983	1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	2101	2102	2103	2104	2105	2106	2107	2108	2109	2110	2111	2112	2113	2114	2115	2116	2117	2118	2119	2120	2121	2122	2123	2124	2125	2126	2127	2128	2129	2130	2131	2132	2133	2134	2135	2136	2137	2138	2139	2140	2141	2142	2143	2144	2145	2146	2147	2148	2149	2150	2151	2152	2153	2154	2155	2156	2157	2158	2159	2160	2161	2162	2163	2164	2165	2166	2167	2168	2169	2170	2171	2172	2173	2174	2175	2176	2177	2178	2179	2180	2181	2182	2183	2184	2185	2186	2187	2188	2189	2190	2191	2192	2193	2194	2195	2196	2197	2198	2199	2200	2201	2202	2203	2204	2205	2206	2207	2208	2209	2210	2211	2212	2213	2214	2215	2216	2217	2218	2219	2220	2221	2222	2223	2224	2225	2226	2227	2228	2229	2230	2231	2232	2233	2234	2235	2236	2237	2238	2239	2240	2241	2242	2243	2244	2245	2246	2247	2248	2249	2250	2251	2252	2253	2254	2255	2256	2257	2258	2259	2260	2261	2262	2263	2264	2265	2266	2267	2268	2269	2270	2271	2272	2273	2274	2275	2276	2277	2278	2279	2280	2281	2282	2283	2284	2285	2286	2287	2288	2289	2290	2291	2292	2293	2294	2295	2296	2297	2298	2299	2300	2301	2302	2303	2304	2305	2306	2307	2308	2309	2310	2311	2312	2313	2314	2315	2316	2317	2318	2319	2320	2321	2322	2323	2324	2325	2326	2327	2328	2329	2330	2331	2332	2333	2334	2335	2336	2337	2338	2339	2340	2341	2342	2343	2344	2345	2346	2347	2348	2349	2350	2351	2352	2353	2354	2355	2356	2357	2358	2359	2360	2361	2362	2363	2364	2365	2366	2367	2368	2369	2370	2371	2372	2373	2374	2375	2376	2377	2378	2379	2380	2381	2382	2383	2384	2385	2386	2387	2388	2389	2390	2391	2392	2393	2394	2395	2396	2397	2398	2399	2400	2401	2402	2403	2404	2405	2406	2407	2408	2409	2410	2411	2412	2413	2414	2415	2416	2417	2418	2419	2420	2421	2422	2423	2424	2425	2426	2427	2428	2429	2430	2431	2432	2
--	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	---

(b) evaluating whether the plasma sample contains nucleic acid encoding HIV reverse transcriptase having a mutation at codon 103;

8 wit

53. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

(a) introducing a resistance test vector comprising a patient-derived segment further comprising a mutation at codon 230 and a mutation at codon 181 and an indicator gene into a host cell;

(b) culturing the host cell from step (a);

(c) measuring the indicator in a target host cell; and

(d) comparing the measurement of the indicator from step (c) with the measurement of the indicator measured when steps (a) - (c) are carried out in the absence of the candidate antiretroviral drug compound;

wherein a test concentration of the candidate antiretroviral drug compound is present at steps (a) - (c); at steps (b) - (c); or at step (c).

54. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

(a) introducing a resistance test vector comprising a patient-derived segment further comprising a mutation at codon 181 and a mutation at codon 98 and/or 106 and/or 227 and an indicator gene into a host cell;

(b) culturing the host cell from step (a);

(c) measuring the indicator in a target host cell; and

(d) comparing the measurement of the indicator from step (c) with the measurement of the indicator measured when steps (a) - (c) are carried out in the

Sub 17

669666-669666

absence of the candidate antiretroviral drug compound;

wherein a test concentration of the candidate antiretroviral drug compound is present at steps (a) - (c); at steps (b) - (c); or at step (c).

55. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

- Sub. C17*
 659250-6520360
- (a) introducing a resistance test vector comprising a patient-derived segment further comprising a mutation at codon 188 and a mutation at codon 138 and/or 103 and/or 100 and an indicator gene into a host cell;
 - (b) culturing the host cell from step (a);
 - (c) measuring the indicator in a target host cell; and
 - (d) comparing the measurement of the indicator from step (c) with the measurement of the indicator measured when steps (a) - (c) are carried out in the absence of the candidate antiretroviral drug compound;

wherein a test concentration of the candidate antiretroviral drug compound is present at steps (a) - (c); at steps (b) - (c); or at step (c).

56. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

- (a) introducing a resistance test vector comprising a patient-derived segment further comprising a mutation

at codon 190 and a mutation at codon 98 and/or 101 and/or 103 and an indicator gene into a host cell;
 (b) culturing the host cell from step (a);
 (c) measuring the indicator in a target host cell; and
 (d) comparing the measurement of the indicator from step (c) with the measurement of the indicator measured when steps (a) - (c) are carried out in the absence of the candidate antiretroviral drug compound;

wherein a test concentration of the candidate antiretroviral drug compound is present at steps (a) - (c); at steps (b) - (c); or at step (c).

57. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:
 (a) introducing a resistance test vector comprising a patient-derived segment further comprising a mutation at codon 106 and a mutation at codon 227 and/or 189 and an indicator gene into a host cell;
 (b) culturing the host cell from step (a);
 (c) measuring the indicator in a target host cell; and
 (d) comparing the measurement of the indicator from step (c) with the measurement of the indicator measured when steps (a) - (c) are carried out in the absence of the candidate antiretroviral drug compound;

wherein a test concentration of the candidate antiretroviral drug compound is present at steps (a) - (c); at steps (b) - (c); or at step (c).

58. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

- Sub. C17
- (a) introducing a resistance test vector comprising a patient-derived segment further comprising a mutation at codon 103 and a mutation at codon 100 and an indicator gene into a host cell;
 - (b) culturing the host cell from step (a);
 - (c) measuring the indicator in a target host cell; and
 - (d) comparing the measurement of the indicator from step (c) with the measurement of the indicator measured when steps (a) - (c) are carried out in the absence of the candidate antiretroviral drug compound;

wherein a test concentration of the candidate antiretroviral drug compound is present at steps (a) - (c); at steps (b) - (c); or at step (c).

59. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

- (a) introducing a resistance test vector comprising a patient-derived segment which encodes the reverse transcriptase having a mutation at codon 230 and an indicator gene into a host cell;

(b) culturing the host cell from step (a);

(c) measuring expression of the indicator gene in a target host cell; and

(d) comparing the expression of the indicator gene from step (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the candidate anti-viral drug compound,

wherein a test concentration of the candidate anti-viral drug compound is present at steps (a)-(c); at steps (b)-(c); or at step (c).

60. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

(a) introducing a resistance test vector comprising a patient-derived segment which encodes the reverse transcriptase having a mutation at codon 227 and an indicator gene into a host cell;

(b) culturing the host cell from step (a);

(c) measuring expression of the indicator gene in a target host cell; and

(d) comparing the expression of the indicator gene from step (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the candidate anti-viral drug compound,

6036311 00000000

Sub. C17

wherein a test concentration of the candidate anti-viral drug compound is present at steps (a)-(c); at steps (b)-(c); or at step (c).

61. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

- Sub. C17*
- (a) introducing a resistance test vector comprising a patient-derived segment which encodes the reverse transcriptase having a mutation at codon 188 and an indicator gene into a host cell;
 - (b) culturing the host cell from step (a);
 - (c) measuring expression of the indicator gene in a target host cell; and
 - (d) comparing the expression of the indicator gene from step (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the candidate anti-viral drug compound,

wherein a test concentration of the candidate anti-viral drug compound is present at steps (a)-(c); at steps (b)-(c); or at step (c).

62. A method for assessing the biological effectiveness of a candidate HIV antiretroviral drug compound comprising:

- (a) introducing a resistance test vector comprising a patient-derived segment which encodes the reverse

[illegible]

- wherein a test concentration of the candidate anti-viral drug compound is present at steps (a)-(c); at steps (b)-(c); or at step (c).

63. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutation at codon 230 and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

64. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutation at codon 227 and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

65. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutation at codon 188 and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

Sub. C17
66. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutation at codon 189 and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

669220-66202660
67. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutations at codon 181, codon 98, codon 106 and codon 227 or a combination thereof and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

68. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutations at codon 106, codon 227, and codon 189 or a combination thereof and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

69. A resistance test vector comprising an HIV patient-derived segment further comprising reverse transcriptase having a mutations at codon 103 and codon 101 and an indicator gene, wherein the expression of the indicator gene is dependent upon the patient derived segment.

*Sub
all C1*

70. The resistance test vector of claim 17, wherein the patient-derived segment having a mutation at codon 190 further comprises mutations at codon 98 and codon 101 or a combination thereof.

71. The resistance test vector of claim 63, wherein the patient-derived segment having a mutation at codon 230 further comprises a mutation at codon 181.

72. The resistance test vector of claim 65, wherein the patient-derived segment having a mutation at codon 188 further comprises mutations at codon 138, codon 103 and codon 190 or a combination thereof.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.